• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • France

PAI-backed Ethypharm acquires Martindale Pharma

  • Alice Tchernookova
  • Alice Tchernookova
  • @alicetcherno
  • 19 January 2017
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Acquired by PAI Partners last year, pharmaceutical company Ethypharm has bolted on UK-based group Martindale Pharma.

A definitive agreement has been signed between both firms, the GP said in a statement. The combined group will generate revenues in excess of €300m, PAI said.

Martindale’s CEO Michael Harris will take up the role of chief operating officer at Ethypharm as part of the transaction.

Martindale Pharma

  • DEAL:

    Portfolio management

  • LOCATION:

    Essex

  • SECTOR:

    Pharmaceuticals

  • FOUNDED:

    1990

The addition of Martindale will reinforce Ethypharm's presence in the UK, the GP claimed.

Manufacturing capabilities will also be enhanced, especially for solid dose, injectables and oral liquids. The combined group will look to expand further into the fields of emergency care, pain and addiction, with plans to take its products into new markets where access to medicine needs improvement.

No new equity was added for the transaction, the GP told unquote".

Previous funding
PAI acquired French drug-maker Ethypharm from fellow private equity firm Astorg Partners in a deal reportedly valued at €725m in May 2016. The GP acquired the firm alongside the firm's management team.

Equity for the transaction was provided by PAI Europe VI, a €3.3bn fund, closed in July 2015 above its €2.5bn target. The deal reportedly valued Ethypharm at 11x its 2015 EBITDA of €66m. PAI saw off competing bids from private equity rival Bain Capital and European pharmaceutical firm Mundipharma, Reuters reported.

Astorg acquired a 60% stake in the company in 2007 via its fourth buyout fund, the €800m Astorg IV vehicle. According to unquote" data, the deal was valued in the £100-250m range, with CEO Gerard Leduc and the management team retaining a 29% interest in the company, and Intermediate Capital Group and other investors holding the remainder of the equity. In 2013, GE Capital and Ares Management provided Ethypharm with a €170m unitranche facility. GE and Ares arranged the facility via their $1.75bn European Senior Secured Loan Programme unitranche joint venture. It refinanced Ethypharm's existing debt and was earmarked to fund both R&D and future acquisitions.

Company
Based in Saint-Cloud, near Paris, Ethypharm specialises in pain and addiction treatment. It operates in 30 countries worldwide, having recently expanded into the UK with the acquisition of pharmaceuticals provider DB Ashbourne. The company also provides generic drugs to treat stomach and intestinal problems, as well as cardiovascular diseases. It currently employs 950 people and has a network of 80 partners worldwide, generating revenues of €200m.

Martindale is a speciality pharmaceutical company providing essential medicines to around 50 countries around the world, with a heavy focus on the UK and the Middle East. The group is a recognised strategic partner of the NHS and other healthcare providers, and supplies 100 licensed products.

People 
PAI Partners - Frederic Stevenin, Stefano Drago (partners). 

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • France
  • UK / Ireland
  • Portfolio management
  • Healthcare
  • France
  • Build-up
  • PAI Partners
  • Astorg Partners

More on France

EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
EU foreign subsidies regulations
EU FSR could impact PE fundraising with potential rise in ‘clean funds’

FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely

  • Regulation
  • 01 September 2023
Mergermarket
Letter from the editor: Unquote is moving to Mergermarket

Unquote Editor Harriet Matthews outlines Unquote.com's upcoming move to the Mergermarket platform and the new capabilities and intelligence that this brings to Unquote readers

  • Industry
  • 30 August 2023
Pensions administration software providers
IK Investment-backed Eres expected to hit the auction block by 2024

French employee savings distribution and management firm could be valued at a few hundred million euros

  • Exits
  • 24 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013